0001193125-19-263824.txt : 20191007 0001193125-19-263824.hdr.sgml : 20191007 20191007170806 ACCESSION NUMBER: 0001193125-19-263824 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20191003 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20191007 DATE AS OF CHANGE: 20191007 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jazz Pharmaceuticals plc CENTRAL INDEX KEY: 0001232524 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981032470 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33500 FILM NUMBER: 191141385 BUSINESS ADDRESS: STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE STREET 2: WATERLOO ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 353-1-634-7800 MAIL ADDRESS: STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE STREET 2: WATERLOO ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: JAZZ PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030513 8-K 1 d818165d8k.htm 8-K 8-K
NASDAQ false 0001232524 0001232524 2019-10-03 2019-10-03

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

October 3, 2019

Date of Report (Date of earliest event reported)

 

JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY

JAZZ PHARMACEUTICALS PLC

(Exact name of registrant as specified in its charter)

 

Ireland

  

001-33500

 

98-1032470

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File No.)

  

(IRS Employer

Identification No.)

Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland D04 E5W7

(Address of principal executive offices, including zip code)

011-353-1-634-7800

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Ordinary shares, nominal value $0.0001 per share

  

JAZZ

  

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Matthew P. Young has notified Jazz Pharmaceuticals plc (the “Company”) of his decision to resign from his position as Executive Vice President and Chief Financial Officer of the Company, effective as of October 25, 2019 (the “Resignation Date”), in order to pursue a leadership opportunity with a privately-held healthcare company. Mr. Young’s resignation is not due to any disagreement relating to the Company’s operations, financial statements, internal controls, auditors, policies or practices. The Company expects that Mr. Young will continue as a consultant to the Company during a transition period following the Resignation Date to assist with the preparation and filing of the Company’s next Quarterly Report on Form 10-Q and with the transition of his duties and responsibilities.

Effective as of the Resignation Date, Bruce C. Cozadd, the Company’s Chairman and Chief Executive Officer, will assume the duties and responsibilities of the Company’s principal financial officer on an interim basis while the Company conducts a search for Mr. Young’s replacement. Mr. Cozadd, age 56, co-founded Jazz Pharmaceuticals, Inc. in 2003 and has served as the Company’s Chairman and Chief Executive Officer since April 2009. Additional biographical information for Mr. Cozadd may be found in the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on June 14, 2019.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY

     

By:

 

/s/ Bruce C. Cozadd

Name:

 

Bruce C. Cozadd

Title:

 

Chairman and Chief Executive Officer

Date: October 7, 2019

EX-101.SCH 2 jazz-20191003.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 jazz-20191003_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, Country Entity Address, Country Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 jazz-20191003_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 7 0001193125-19-263824-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-19-263824-xbrl.zip M4$L#!!0 ( *)1T]Q3$0HC@\ .M< . 9#@Q.#$V-60X:RYH=&WM M'&ES(K?R^ZMZ_T'%OB3>*G,,X ML4BS&&Q)? >_+\24E9@3H[3":2!H;]M>_ M;LW! (,!'^O-KEUEFT$M=:LO=4NM.?YQ,G;)+9.*"^\D9Q5*.<(\6SC<&Y[D M CW('^;(CXU__^MXI $0@#U510>,;15_OSCOV2,VIGGN*4T].\$2:+F2IJ,B MM,: 7(EJV3JX9P(11-)AL@K6 E@/ILM^?]<]GX'K;/@9:%%+ZJF! YH4!\< M:2]?*N?+^ZE!\J <

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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 1 97 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d818165d8k.htm jazz-20191003.xsd jazz-20191003_lab.xml jazz-20191003_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d818165d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d818165d8k.htm" ] }, "labelLink": { "local": [ "jazz-20191003_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "jazz-20191003_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "jazz-20191003.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "jazz", "nsuri": "http://www.jazzpharma.com/20191003", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d818165d8k.htm", "contextRef": "duration_2019-10-03_to_2019-10-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d818165d8k.htm", "contextRef": "duration_2019-10-03_to_2019-10-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jazzpharma.com//20191003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 13 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Document and Entity Information
Oct. 03, 2019
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001232524
Document Type 8-K
Document Period End Date Oct. 03, 2019
Entity Registrant Name JAZZ PHARMACEUTICALS PLC
Entity Incorporation State Country Code L2
Entity File Number 001-33500
Entity Tax Identification Number 98-1032470
Entity Address, Address Line One Fifth Floor
Entity Address, Address Line Two Waterloo Exchange
Entity Address, Address Line Three Waterloo Road
Entity Address, City or Town Dublin 4
Entity Address, Country IE
Entity Address, Postal Zip Code D04 E5W7
City Area Code 011-353-1
Local Phone Number 634-7800
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Ordinary shares, nominal value $0.0001 per share
Trading Symbol JAZZ
Entity Emerging Growth Company false

XML 14 d818165d8k_htm.xml IDEA: XBRL DOCUMENT 0001232524 2019-10-03 2019-10-03 NASDAQ false 0001232524 8-K 2019-10-03 JAZZ PHARMACEUTICALS PLC L2 001-33500 98-1032470 Fifth Floor Waterloo Exchange Waterloo Road Dublin 4 IE D04 E5W7 011-353-1 634-7800 false false false false Ordinary shares, nominal value $0.0001 per share JAZZ false